In a landmark development for public health in England, the National Institute for Health and Care Excellence (NICE) has recommended that Wegovy — the brand name for the weight-loss drug semaglutide — be made available to over 1.2 million more patients on the NHS. The announcement, made in late March 2026, marks a significant expansion of access to a medication that has already transformed the treatment of obesity in the UK.
What Is Wegovy?
Wegovy is an injectable medication containing semaglutide, a GLP-1 receptor agonist originally developed to treat type 2 diabetes. When used for weight management, it works by mimicking a naturally occurring hormone that regulates appetite, leading users to feel fuller sooner and consume fewer calories overall.
Clinical trials have shown that patients using Wegovy alongside lifestyle changes can lose an average of 15–17% of their body weight — results that were previously only achievable through bariatric surgery. This has led many clinicians to describe semaglutide as the most significant advance in obesity treatment in a generation.
The New NICE Recommendation
The latest NICE guidance, announced on 31 March 2026, extends eligibility for Wegovy on the NHS to patients who are overweight and have previously suffered a heart attack, stroke, or have serious circulation problems in their legs — conditions known collectively as established cardiovascular disease.
This new indication is based on compelling evidence that semaglutide significantly reduces the risk of further cardiovascular events. A major clinical study found that patients with obesity and cardiovascular disease who took the drug experienced a 20% reduction in the risk of heart attack or stroke compared to those on a placebo — even among patients who lost little weight.
In practical terms, this means approximately 1.2 million more people in England could become eligible for the drug through NHS prescription, adding to the hundreds of thousands already accessing it through specialist weight management services.
Who Can Currently Get Wegovy on the NHS?
Access to NHS Wegovy remains subject to specific clinical criteria. Currently, patients may be eligible if they:
- Have a BMI of 35 or above (or 32.5+ for South Asian, Black African or Caribbean, or other high-risk ethnic groups)
- Have at least one weight-related health condition, such as type 2 diabetes, hypertension, or high cholesterol
- Have not successfully lost weight through diet and exercise alone
- Are referred through a specialist weight management service
With the new cardiovascular recommendation, patients with a BMI from 27 upwards who have had a previous heart attack or stroke may also now qualify — a considerably lower threshold that broadens access substantially.
Supply Challenges and Waiting Times
Despite the positive news, practical access to Wegovy on the NHS remains constrained. A well-documented global shortage of semaglutide — driven by surging demand both on prescription and through private weight-loss clinics — has meant that many eligible patients have faced long waits.
NHS England has implemented a prioritised rollout, focusing on those with the most acute medical need first. This phased approach has drawn criticism from patient groups, who point out that people who could most benefit from treatment are still waiting months or even years for access.
The Government has been working with Novo Nordisk, the Danish pharmaceutical company that manufactures Wegovy, to increase supply to England. However, global manufacturing constraints mean that a substantial easing of shortages is not expected until late 2026 at the earliest.
The Private Market and NHS Inequity
One of the more contentious aspects of the Wegovy expansion story is the stark contrast between NHS access and the private market. Patients who can afford to pay privately — typically between £150 and £300 per month — can obtain the drug relatively quickly through online clinics and pharmacies.
This has led to accusations of a “two-tier” system, where wealthier patients can bypass NHS waiting lists while those on lower incomes — who are, statistically, more likely to suffer from obesity and related conditions — face the longest delays.
What About Wegovy Pills?
Currently, Wegovy is only available as a weekly injection. However, an oral pill version of semaglutide is in the pipeline. The Medicines and Healthcare products Regulatory Agency (MHRA) is currently reviewing the data on the pill formulation, with a decision expected in late 2026. If approved, NHS access would likely follow in 2027 — though exact timelines remain uncertain.
For now, the expanded injectable form represents a significant step forward. For the 1.2 million patients newly eligible, it offers the possibility of meaningful health improvements — and in some cases, life-saving prevention of future cardiac events.